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Pharmaceutical inhibitors of aminoacyl-tRNAsynthe-
tases demand high species and family specificity.
The antimalarial ATP-mimetic cladosporin selectively
inhibits Plasmodium falciparum LysRS (PfLysRS).
How the binding to a universal ATP site achieves
the specificity is unknown. Here we report three crys-
tal structures of cladosporin with human LysRS,
PfLysRS, and a Pf-like human LysRS mutant. In all
three structures, cladosporin occupies the class
defining ATP-binding pocket, replacing the adeno-
sine portion of ATP. Three residues holding themeth-
yltetrahydropyran moiety of cladosporin are critical
for the specificity of cladosporin against LysRS over
other class II tRNA synthetase families. The spe-
cies-exclusive inhibition of PfLysRS is linked to a
structural divergence beyond the active site that
mounts a lysine-specific stabilizing response to bind-
ing cladosporin. These analyses reveal that inherent
divergence of tRNA synthetase structural assembly
may allow for highly specific inhibition even through
the otherwise universal substrate binding pocket
and highlight the potential for structure-driven drug
development.
INTRODUCTION
Aminoacyl-tRNA synthetases (aaRSs) are essential enzymes
for all cellular life. They perform a central role in the translation
of the genetic code by synthesizing aminoacyl-tRNAs, which
are subsequently used for protein synthesis (Ibba and Soll,
2000). Because of their essential role in translation, the inhibitors
of aaRSs are widely used as antimicrobial medicines or rigor-
ously tested in clinical trials for therapeutic applications in cancer
and autoimmune diseases (Gadakh and Van Aerschot, 2012;
Kim et al., 2014; Rock et al., 2007; Silvian et al., 1999; Sundrud
et al., 2009; Zhou et al., 2013).
Inhibitors of aaRSs demand high species and family specificity
for successful therapeutic application. For example, the natural
product mupirocin inhibits bacterial isoleucyl-tRNA synthetase
(IleRS) activity and is widely used as a topical treatment for skin
infections (Silvian et al., 1999). Inhibiting human prolyl-tRNA syn-734 Chemistry & Biology 22, 734–744, June 18, 2015 ª2015 Elsevierthetase (ProRS) (Keller et al., 2012), febrifugine is the active
component of the Chinese herb Chang Shan (Dichroa febrifuga
Lour.), which has been used for treating malaria-induced fever
for about 2,000 years (Jiang et al., 2005). Halofuginone (HF),
the halogenated derivative of febrifugine, has been tested
in clinical trials for the treatment of cancer, fibrotic disease, and
recently, Duchenne muscular dystrophy (Kotz, 2012; Pines
et al., 2003). The boron-containing compound AN2690 binds to
fungal leucyl-tRNA synthetase (LeuRS) and is licensed for the
treatment of onychomycosis (Baker et al., 2006). Theseexamples
highlight the tremendous potential of aaRS inhibitors in medical
applications. Understanding of the mechanism(s) for inhibition
will greatly promote the design of novel therapies.
The 24 known aaRS families are divided into two structurally
distinct classes (class I and class II), each featuring a catalytic
domain with a common fold that binds ATP, amino acid, and
the 30-terminus of tRNA (Delarue and Moras, 1993; Francklyn
et al., 1997; Ribas de Pouplana and Schimmel, 2001). In a com-
mon two-step reaction, the aaRS first catalyzes the activation of
the amino acid by ATP, forming an aminoacyl-adenylate interme-
diate (aa-AMP); then the amino acid is transferred from the inter-
mediate to either the 20- or 30-hydroxyl oxygen atom of the 30-A76
tRNAnucleotide,which functionsasanucleophile in thesynthesis
of aminoacyl-tRNA (Ibba and Soll, 2000). A common class of
aaRS inhibitors mimics aa-AMPs, with a non-hydrolyzable ester
bond between amino acid and the alpha-phosphate, such as
lysyl-sulfide adenylate or glutamyl-sulfide adenylate and other
aminoacyl-sulfide adenylates (aa-SAs) (Belrhali et al., 1994;
Crepin et al., 2006; Cvetesic et al., 2014; Fukai et al., 2000; Guo
et al., 2009; Ito and Yokoyama, 2010; Iwasaki et al., 2006; Kamte-
kar et al., 2003; Kotik-Kogan et al., 2005; Nakanishi et al., 2005;
Sakurama et al., 2009; Sankaranarayanan et al., 2000). Because
these inhibitors directly occupy and block the active site for
ATPand amino acid, they usually display high specificity and tight
binding affinities (nM) to aaRSs (Pope et al., 1998; Vondenhoff
and Van Aerschot, 2011; Zhao et al., 2014). However, due to the
highly charged property of both amino acid and adenylate moi-
eties, these inhibitors generally showed limited whole cell activity
with poor penetration through the cell membrane, and their near
identical structure to thenatural aa-AMPsalso causespoor selec-
tivity against aaRSs from different species, limiting their potential
application for therapy (Hurdle et al., 2005). Therefore continuous
efforts have been taken to explore novel inhibitors for aaRSswith
high potency and specificity.
Cladosporin (CP) is a secondary metabolite produced
by various fungal genera such as Cladosporium, Eurotium,Ltd All rights reserved
Figure 1. Specific Recognition of CP by Human LysRS
(A) Chemical structure of cladosporin (CP).
(B) Overview of HsLysRS-CP structure determined at a resolution of 2.1 A˚. A LysRS dimer is shown in cartoon and transparent surface, and CP molecules are
shown in orange spheres. Anticodon binding domains (ABD) are colored cyan and black. Catalytic domains (CD) are colored green and white. The conserved
motifs I, II, and III are colored yellow, blue, and pink, respectively.
(C) Two-dimensional presentation of CP binding in HsLysRS. CP and hydrogen-bonding residues are shown in stick representations, and other residues within
4.5A˚ of CP are shown in light green.
(D) Zoom-in view of CP localization in the conserved ATP binding site of LysRS. CP and residues within 5 A˚ of CP are shown as sticks. The 2Fo-Fc electrodensities
of CP and co-bound lysine are shown as black meshes with 1.5 s.
(E) Zoom-in view of ATP localization in HsLysRS (PDB: 3BJU). ATP and residues within 5 A˚ of ATP are shown as sticks. (See also Figure S1).Aspergillus, and Chaetomium (Scott et al., 1971) and it exhibits
potent antibiotic activity (Hoepfner et al., 2012; Kimura et al.,
2012; Scott et al., 1971; Springer et al., 1981). CP shows great
potential in agricultural applications for developing treatment
and management of plant diseases. CP at 30 mM was shown
to be able to inhibit the growth of plant pathogensColletotrichum
acutatum, Colletotrichum fragariae, Colletotrichum gloeospor-
ioides, and Phomopsis viticola by over 80% (Wang et al.,
2013). CP has even stronger growth-inhibitory activities againstChemistry & Biology 22,both blood- and liver-stage Plasmodium falciparum parasite
forms with an IC50 (inhibitory concentration 50%) of 40–90 nM,
while having little effect on the growth of human cells (Hoepfner
et al., 2012). By haploinsufficiency chemogenomic profiling in
yeast, the cellular target of CP was recently identified to be cyto-
solic lysyl-tRNA synthetases (LysRS) (Hoepfner et al., 2012).
With amolecular weight of 292.3 Da and isocoumarin-contain-
ing structure thatmimics the adenosine group of ATP (Figure 1A),
CP possesses a high selectivity index against Plasmodium734–744, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 735
parasites compared with mammalian cells (IC50/CC50 [cytotoxic
concentration at which 50% cytotoxicity is observed] > 111),
promising great potential as a future antimalarial (Hoepfner
et al., 2012). A recent research report described a co-crystal
structure of CP with P. falciparum LysRS (PfLysRS) and sug-
gested that two residues (V328 and S344) frommotif 2 determine
the selectivity of CP against PfLysRS (Khan et al., 2014).
However, mutagenesis of these two residues rescued only 4%
of the 1,000-fold specificity in yeast LysRS (Hoepfner et al.,
2012). Since CP shares little in common with previously
characterized aaRS inhibitors, the details of its binding mode
and mechanism of selectivity, particularly to human LysRS
(HsLysRS), remain unclear.
Here we thoroughly investigated this question by determining
and analyzing three crystal structures of CP in complex with
HsLysRS,PfLysRS, and a Pf-like human LysRSmutant at resolu-
tionsof 2.1 A˚, 3.4 A˚, and2.9 A˚, respectively.CPoccupies theclass
defining ATP-binding pocket in the class II LysRS dimer. Three
smaller residues at the bottom of the ATP-binding pocket hold
and interact with the methyltetrahydropyran group of CP, critical
for its specificity against LysRS over other class II tRNA synthe-
tase families. In contrast to the low activity against human LysRS,
CPbinds tobothhumanandPlasmodiumLysRSs in anearly iden-
tical mode in the active site. The active site-mimicking Pf-like
human LysRS mutant failed to replicate the significant species
specificityofCP.SinceCPco-bindswith lysine in all threeof these
structures (including our HsLysRS-K-CP, and Pf-like human
LysRS-K-CP structures and one previous solved PfLysRS-
K-CP), we determined a fourth structure of PfLysRS-CP without
lysine. Analysis of this structure unveiled a lysine-dependent
structural divergence of LysRS outside the active site that may
lead to a cooperative binding of CP and lysine. The hypothesis
was validatedbyadiscovery that co-bindingofCPand lysine trig-
gers a specific gainof stability forPfLysRSbut notHsLysRSor the
Pf-like human LysRS. Overall, this work exhibits that two features
of aaRSs, the inherent divergence of tRNA synthetase structure
and the cooperative binding of cognate amino acid, together
could allow for highly specific inhibition through the universal
pocket for ATP. This study thus provides important implications
in the future drug development for tRNA synthetases.
RESULTS
Recognition of CP by Human LysRS
CP is a composite of a (6,8)-dihydroxyl-isocoumarin group and
a methyltetrahydropyran group, linked by a methylene at the 30
position of the isocoumarin (Figure 1A). To determine the com-
plex structure ofHsLysRS with CP, we soakedHsLysRS crystals
pre-crystallized with lysine, in a solution containing 3 mM CP
and determined the structure at a resolution of 2.1 A˚ (Table 1).
The CP molecule binds in each aminoacylation active site of
the HsLysRS dimer (Figure 1B). Complete and clear densities
for both CP and a co-bound lysine were observed with 100%
occupancies (Figures 1C and 1D, and S1A), where CP occupies
only the ATP binding site. This ternary structure of HsLysRS-
K-CP (K denotes the presence of lysine) suggests that CP binds
LysRS through competing with ATP but not lysine.
The previous PfLysRS-K-CP structure indicated that CP was
bound in the ATP binding site (Khan et al., 2014). Without the cor-736 Chemistry & Biology 22, 734–744, June 18, 2015 ª2015 ElsevierrespondingPfLysRS-ATP structure, however, the exact similarity
between the recognitions of CP and ATP in LysRS remains unde-
fined. Comparing this new HsLysRS-K-CP structure with our
previously determined HsLysRS-K-ATP structure (Guo et al.,
2008), the isocoumarin group of CP occupies a position corre-
sponding to the adenine portion of ATP in the active site (Figures
1D and 1E, and S1B). Particularly, E325 forms an H bondwith the
6-OH group on the isocoumarin, mimicking the H bond between
E325 with the 7-OH group on the adenosine of ATP (Figures 1D
and 1E). The 1-ketone group of CP forms another hydrogen
bond with R553, which forms salt bridges with the g-phosphate
of ATP in the ATP-bound structure (Figures 1D and 1E). Main
chain atoms of N332 form two additional H-bonding interactions
with the 8-OH group, which is not present on ATP (Figure 1D).
Another shared interaction of CP with ATP is a stacking interac-
tion with the benzene ring of F335 (Figures 1D and 1E). F335 is
located on the class II characteristic Motif 2 of LysRS; together
with E325 and H331, they form a conserved ATP binding loop
in LysRS and are also partially conserved in the rest of other
class II aaRSs (Cusack, 1997). Instead of the proposal that the
entire CP mimics ATP (Hoepfner et al., 2012; Khan et al., 2014),
these additional structural analyses reveal that it is the isocou-
marin moiety of CP sharing key interactions of the adenosine
group of ATP to bind LysRS (Figures S1C and S1D).
The rest of the CP structure interacts with LysRS in a manner
distinct from ATP. A methyltetrahydropyran ring occupies the
space for the ribose group of ATP (Figure S1C), with essentially
all hydrophobic interactions, formed by surrounding residues
R323, T337, E494, I495, C496, N497, G548, G550, and R553
(Figure 1D). Instead, in the ribose group of ATP, the 20-OH group
forms H bonds with the main chain atoms of E494, I495, and
G550, while the 30-OH group forms an H bondwith the side chain
of E494 (Figure 1E). The C1 and C4 atoms of the ribose ring form
two other hydrophobic interactions with F335 and T337.
The three phosphate groups of ATP are recognized by LysRS
through Mg2+ coordinated interaction with the class-conserved
residues E494 on motif 3 and another nearby acetic residue
E487 (Figures 1E and S1B). In contrast, CP does not contain
phosphate groups and thus no Mg2+ were found in the
HsLysRS-K-CP electronic density (Figure S1A). Instead, E494
contributed a hydrophobic interaction with CP through the
aliphatic portion (Cb–Cd) of its side chain. Most of the residues
involved in the interactions with ATP are also found to interact
with CP, with the isocoumarin group of CP replacing the adenine
portion of ATP, and the methyltetrahydropyran group of CP re-
placing the ribose group of ATP (Figure 1D). Collectively, these
results reveal that the inhibitory action against LysRS by CP is
based on limited ATP mimicry, with partially overlapped struc-
tures and induced conformation changes of interacting residues.
Basis of the Family Specificity of CP against LysRS
The 24 aaRS families are classified into two classes, character-
ized by a distinct fold of the catalytic domains (Figure S2A)
(Rossmann fold for class I and seven-strand b sheet for class
II), which each originated from a specific ATP-binding fold (De-
larue andMoras, 1993; Francklyn et al., 1997; Ribas de Pouplana
and Schimmel, 2001). Previous genomic screening indicated
that among a collection of 5,803 genes in yeast covering
95% of the yeast genome including all the cytoplasmic andLtd All rights reserved
Table 1. Crystallographic Statistics of LysRS-CP Complex Structures
HsLysRS-K-CP Pf-like Human LysRS-K-CP PfLysRS-CP
Data Collection
Space group C2221 P1 P21
Cell dimensions
a, b, c (A˚) 96.17, 99.93, 269.78 51.28, 75.56, 162.99 70.63, 112.10, 170.80
a, b, g () 90.00, 90.00, 90.00 90.80, 99.09, 109.83 90.00, 99.30, 90.00
Resolution (A˚) 50.00–2.10 (2.18–2.10)a 40.00–2.90 (3.00–2.90) 50.00–3.40 (3.52–3.40)
Rsym or Rmerge (%) 10.2 (70.9) 8.7 (45.3) 19.8 (53.8)
I/sI 19.7 (2.7) 9.5 (1.8) 7.0 (2.6)
Completeness (%) 99.9 (100.0) 93.5 (90.2) 96.5 (94.5)
Redundancy 7.4 (7.6) 2.1 (2.1) 3.9 (3.7)
Refinement
Resolution (A˚) 50.00–2.10 (2.17–2.10) 40.00–2.90
(3.00–2.90)
50.00–3.40 (3.53–3.40)
No. reflections 72,043 (4,465) 44,957 (2,816) 34,557 (3,157)
Rwork/Rfree (%) 19.1/21.3 22.3/26.8 22.7/26.0
No. atoms
Protein 8288 15,911 15,165
CP 42 84 84
L-lysine 20 40 –
Solvent 700 9 7
B factors (A˚2)
Protein 31.0 62.6 59.3
CP 21.4 44.6 40.9
L-lysine 18.9 38.5 –
Solvent 38.1 28.9 27.8
Rmsd
Bond lengths (A˚) 0.006 0.005 0.006
Bond angles () 1.045 0.970 1.240
Ramachandran plot
Most favored (%) 98.0 97.0 96.0
Additional allowed (%) 2.0 3.0 4.0
aValues in parentheses are for highest-resolution shell.mitochondrial aaRSs, only cytoplasmic LysRS could rescue the
inhibition of CP on cells (Hoepfner et al., 2012). Since themode of
ATP binding structure is strictly conserved within each aaRS
class, the fact that CP specifically binds to and inhibits LysRS
rather than other class II aaRSs is astonishing, and the mecha-
nism remains unclear.
In contrast to class I aaRSs, in which ATP is held in an
extended conformation by their two signature motifs HIGH and
KMSKS, the class II aaRSs, including PfLysRS and HsLysRS,
stabilize ATP in a bent form that sits between the class II charac-
teristic motif 2 and motif 3 (Cusack, 1993; Eriani et al., 1990).
We modeled the CP molecule in nine of 13 class II aaRS
structures, by superimposing the adenine group of ATP in
aaRS structures onto the isocoumarin group of the LysRS-CP
structure (Figure 2 and Figure S2B). In the HsLysRS enzymatic
center, the ATP/adenine binding pocket residues R323, H331,
F335, and R553 contribute to 58% of the total atomic interac-
tions (111 of 191) for CP. These residues are conserved in nearly
all class II aaRSs and thus may lead to a general inhibition. OnChemistry & Biology 22,the other side, T337, G548, and G550 form hydrophobic inter-
actions with the methyltetrahydropyran moiety from the bottom
of the ATP pocket (Figure 2A). These three residues are located
3.7 A˚, 3.4 A˚, and 6.0 A˚ away from the ribose moiety of ATP
(Figure S2B). They are highly variable in other class II aaRSs
(Figures 2B–2I). For example, the corresponding residues are
K323, T429, and A432 in human seryl-tRNA synthetase (SerRS).
They are all larger than the counterparts in LysRS, forming
stereo clashes with the modeled CP (Figure 2B). Similarly, two
larger-residue substitutions of the three are common in ProRS,
threonyl-tRNA synthetase (ThrRS), phenylalanyl-tRNA synthe-
tase (PheRS), glycyl-tRNA synthetase (GlyRS) and histidyl-
tRNA synthetase (HisRS) (Figures 2C–2G), indicating potential
steric repulsions. Asparaginyl-tRNA synthetase (AsnRS), aspar-
tyl-tRNA synthetase (AspRS), and LysRS belong to the same
sub-class (class IIb) (Ribas de Pouplana and Schimmel, 2001).
Only one of the three residues is replaced in AsnRS or AspRS.
In AsnRS the T337 is replaced by a H336 (Figure 2H), which
clashes with the modeled CP molecule at the methyl group,734–744, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 737
Figure 2. Structural Basis of the Selectivity of CP among class II aaRSs
(A) In a human LysRS enzymatic center, themethyltetrahydropyran group forms hydrophobic interactions with T337, G548, and G550, which are highly variable in
other class II aaRSs.
(B) The corresponding residues are K323, T429, and A432 in human SerRS (wheat, PDB: 4L87). The three residues are larger than those in LysRS and thus
potentially form stereo clashes with CP.
(C–H) Similarly, W1169 and T1276 in human ProRS (light blue, PDB: 4HVC), Q460 and S596 in human ThrRS (pale yellow, PDB: 4P3N), Q372 and S460 in human
PheRS (light pink, PDB: 3L4G), M348 and S578 in human GlyRS (pale cyan, PDB: 2ZT5), Q173 and S383 in human HisRS (light orange, PDB: 4G84), and H336 in
Brugia malayi AsnRS (blue white, PDB: 2XGT) prevent CP from binding by stereo repulsion.
(I) The T337 residue is replaced by a G288 in human AspRS (PDB: 4J15), causing one hydrophobic interaction missing for CP binding. (See also Figures S2).while in AspRS, the T337 is replaced by a G288 (Figure 2I), re-
sulting in a potential loss of hydrophobic interaction and binding
affinity to CP. In addition, the selectivity of CP toward bacterial
LysRS may also be linked to T337. In bacterial KRS, the corre-
sponding residue to T337 is a bulkier hydrophobic methionine
(Figure S2C), which makes steric hindrance with the methyl
group of CP. Consistently, with the T-to-M substitution, the
growth of E. coli was not affected by up to 100 mg/ml CP
(Anke, 1979). In fact, these three residues do not always interact
with ATP, nor are they conserved in their own family of aaRSs
among different species (Figure S2). Therefore, the deep diver-738 Chemistry & Biology 22, 734–744, June 18, 2015 ª2015 Elseviergence of class II aaRSs at the ATP site allows for the strict
LysRS-specific inhibition.
Structurally Indistinguishable Binding of CP to Human
and P. falciparum LysRS
Although the above-mentioned residues differentiate LysRS
from other class II aaRSs, it could not explain the strong species
specificity of CP since these three residues are conserved
in eukaryotic LysRSs. CP inhibits PfLysRS with the strongest
potency, 1,000-fold higher than HsLysRS or yeast LysRS in
a yeast-growth-based assay (Hoepfner et al., 2012). For 55%Ltd All rights reserved
Figure 3. Evolutionarily Conserved CP-Binding Modes of HsLysRS and PfLysRS
(A) Superimposition of the structures of HsLysRS-K-CP (this study), PfLysRS-K-CP (PDB: 4PG3), and Pf-like human LysRS-K-CP (this study). K denotes the
crystal structure is obtained in the presence of lysine.
(B) The only three different residues betweenHsLysRS and PfLysRS active sites, with their side chains facing the bound CPmolecules, are denoted and shown as
sticks. The Pf-like human LysRS is made on an HsLysRS scaffold, with these three residues mutated into the PfLysRS corresponding residues.
(C) The CP (black) binding pocket forming residues are shown as sticks and transparent surface. The colorings of the protein residues are same as in (A)
Numbering of residues is according to HsLysRS and the corresponding PfLysRS residues are shown in parentheses.
(D) Diagram of the atomic contacts between CP and LysRSs in the presence of lysine (K) or without the presence of lysine.sequence identity between human and P. falciparum LysRSs,
the structures of human and P. falciparum LysRS exhibit high
similarity. A root-mean-square deviation (rmsd) of 0.772 A˚ was
observed for 412 superimposed Ca atoms (Figure 3A). In the
active center, only three CP-nearby side chains are different
between the two enzymes: P300, Q321, and T337 in HsLysRS
(P303, Q324, and T340 in yeast LysRS) and T307, V328, and
S344 in PfLysRS (Figure 3B). However, Q324V and T340S muta-
tions of yeast LysRS partially increased the sensitivity for CP
inhibition (by 40-fold, thus 4% of the total species selectivity)
(Hoepfner et al., 2012). To further understand whether these
amino acid substitutions are important for the high CP sensitivity
in PfLysRS, we created a P. falciparum mimetic LysRS (Pf-like
human LysRS) by introducing three mutations into human
LysRS: P300T, Q321V, and T337S, so that the Pf-like human
LysRS would have a PfLysRS active site. We then determinedChemistry & Biology 22,the co-crystal structure of Pf-like human LysRS-K-CP complex
(Table 1).
When we align the three LysRS-K-CP structures together
(including our HsLysRS-K-CP, and Pf-like human LysRS-K-
CP structures and one previous solved PfLysRS-K-CP),
the rmsd of all the non-hydrogen atoms of the bound CPs is
only 0.349 A˚, 0.367 A˚, and 0.364 A˚, respectively (Figures 3A
and 3B). The comparison failed to support that CP was better
accommodated in the PfLysRS than in HsLysRS. All CP-nearby
residues are in nearly identical conformation (Figure 3C). In a
more quantified analysis, we calculated the atomic contacts be-
tween CP molecules and the proteins. PfLysRS-K-CP showed
merely 5% more contacts than in HsLysRS for their lysine co-
bound structures (Figure 3D). More surprisingly, the Pf-like hu-
man LysRS, which has an almost identical PfLysRS active site,
showed even fewer (2%) contacts to CP than the HsLysRS734–744, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 739
(Figure 3D). Therefore, the interactive pattern observed in the
Pf-specific active site could not fully explain the 1,000-fold spec-
ificity of CP to PfLysRS.
Lysine-Dependent Species-Specific Stabilization of
PfLysRS by CP
The only factor in the structures of LysRS-K-CP complexes
that remained to be investigated was the co-binding of CP with
lysine (K). For a rigorous comparison of the earlier PfLysRS-
K-CP structure, we further solved the co-crystal structure of
PfLysRS-CP complex without lysine (Table 1 and Figure S3).
In the absence of lysine, the atomic contacts between CP and
PfLysRS decreased about 20% relative to that in the PfLysRS-
K-CP structure (Figure 3D and Figure S3B). Notably, without
lysine, two regions of the PfLysRS-CP catalytic domain showed
altered conformations with PfLysRS-K-CP. The region 403–457,
which forms the upper side of the PfLysRS enzymatic cleft and
20 A˚ away from the bound CP and lysine, opened out by a
3-A˚ shift. Second, a loop next to the bound lysine (5 A˚ away)
composed of residues 282–288 became disordered without
lysine (Figure 4A). Consistent with these structures, the temper-
ature factors (B factors) of the PfLysRS-K-CPwere 17 A˚2 (29%)
lower than the B factors of the PfLysRS-CP, suggesting a more
static structure for PfLysRS-K-CP (Figure 4B). The stabilized re-
gions were mostly localized around the enzymatic pocket of
PfLysRS, but also a general stabilizing effect (lower B factors)
throughout the entire protein. In contrast, while co-binding of
lysine (K) and CP stabilized the lysine and the ATP binding resi-
dues and the mobile side of the enzymatic cleft, PfLysRS-CP
showed similar B factors to the PfLysRS-apo structure, and
thus, the binding of CP alone had little effect on stabilization (Fig-
ure 4B). These lysine-induced structural changes suggest that
CP preferentially binds to PfLysRS through a lysine-dependent
stabilization effect.
To further validate this hypothesis, we examined the stabiliza-
tion of PfLysRS and HsLysRS in solutions by a thermal shift
assay (Khan et al., 2014). CP significantly increased the melting
temperature of PfLysRS by 17.1C only in the presence of lysine;
however, we found it had little stabilization effect on HsLysRS
and Pf-like human LysRS (<2C) even with the presence of lysine
(Figures 4C–4F). Individual or combinations of natural substrates
(lysine, ATP, and metal ions) in the absence of CP increased the
melting temperature of LysRSs only by less than 3C (Figures
4C–4F). Because the ligand-dependent changes in the melting
temperature (DTm) are directly proportional to the ligand disso-
ciation affinity (Kd) (Pantoliano et al., 2001), the Kd between
CP and LysRS was thereby estimated. The presence of lysine
increased the binding affinity of CP in PfLysRS by 625-fold,
and that is 1375-fold tighter than in HsLysRS (Table 2), support-
ing the earlier biochemistry or cell-based results (Hoepfner et al.,
2012).
Replacing lysine with any of the other 19 non-cognate amino
acids did not yield stabilization effect (Figures 4G and 4H), indi-
cating the stabilization effect of CP to PfLysRS is also lysine spe-
cific. Finally, Pf-like human LysRS carrying a mimetic active site
of PfLysRS behaved similar to HsLysRS and was not stabilized
by lysine + CP (Figure 4E), indicating that the stabilization of
LysRS by K-CP co-binding did not rely on the subtly different
binding modes of CP in the active site. Collectively, CP stabilizes740 Chemistry & Biology 22, 734–744, June 18, 2015 ª2015 ElsevierPfLysRS in a lysine-specific, Pf-specific, and binding site-inde-
pendent manner, where the LysRS structure scaffold beyond
the active site supports the basis for this species-specific
response.
DISCUSSION
Specific Inhibition of tRNA Synthetases through the
Universal ATP Pocket
Among the three substrates of aaRSs, only ATP is a universal
substrate, while amino acid and tRNA are unique to each enzyme
family. Because of the inherent specific recognition of amino
acid by aaRSs, the amino acid binding site in the aaRS active
center is often considered to be critical for developing aaRS-
specific inhibitors (Pope et al., 1998; Teng et al., 2013), with
the ATP site used for further binding stabilization (Keller et al.,
2012; Zhou et al., 2013). The binding of natural substrate in
one sub-site could also affect the binding of the inhibitor in other
sub-sites. For example, the binding of HF in the proline and tRNA
sub-sites in ProRS is ATP dependent (Sundrud et al., 2009; Zhou
et al., 2013). Intriguingly, in a distinct manner, CP binds to LysRS
solely through the conserved ATP sub-site without any occu-
pancy of the lysine site.
The specificity of CP to LysRS but not other aaRSs in a
conserved ATP binding site is surprising. The isocoumarin group
of CP mimics the adenine group of ATP. The methyltetrahydro-
pyran group of CP replaces the ribose group of ATP with pure
hydrophobic interactions with LysRS instead of H-bonding inter-
actions, thereby contributing to the specificity of CP. Three short
residues from the bottom of the ATP-binding pocket make
CP perfectly fit in LysRS, while other class II aaRSs have either
larger corresponding side chains (such as ProRS, SerRS, ThrRS,
HisRS, GlyRS, AsnRS, and PheRS) or a shorter side chain
(AspRS) and thus cannot form stable interaction with CP. The
high variability of these three residues among different aaRS
families and in the same aaRS family among different species
denotes their unimportance for the aminoacylation reaction. In
fact, in most analyzed aaRSs, they do not directly interact with
ATP or amino acid (Figure S2). Therefore, through its methylte-
trahydropyran group, CP exploited a nonconserved patch within
the overall conserved ATP-binding pocket to achieve the highly
specific targeting on one aaRS.
Theoretically, it is possible to modify the methyltetrahydro-
pyran group to obtain specific binding to other class II aaRS
other than LysRS. For example, AspRS has a G288 at the posi-
tion of T337 of human LysRS. Replacement of themethyltetrahy-
dropyran by an ethyltetrahydropyran would potentially clash
with the LysRS T337 residue and create more interactions with
AspRS, thus turning the LysRS inhibitor into an AspRS inhibitor.
By uncovering the LysRS-specific recognition by CP, this
study may provide a new direction to develop high-affinity ATP
competitive inhibitors for other aaRSs.
Inherent Structural Divergence Endows the Specific
Inhibition of PfLysRS
High species specificity is fundamental to aaRS inhibitors for
therapeutic applications. For instance, in contrast to aa-SA,
which lacks species specificity because of a near identical mim-
icry of aa-AMP,mupirocin only partially mimics Ile-AMP, and hasLtd All rights reserved
Figure 4. Lysine-Dependent Specific Stabilization of PfLysRS by CP
(A) Superimposition of PfLysRS_Apo (light blue, PDB: 4H02), PfLysRS-CP (lemon, this study), and PfLysRS-K-CP (orange, PDB: 4PG3). Proteins are shown in
cartoon, and a representative CP molecule is shown as spheres.
(B) B factors of PfLysRS_Apo (light blue, PDB: 4H02), PfLysRS-CP (lemon, this study), and PfLysRS-K-CP (orange, PDB: 4PG3) are plotted per residue.
(C) Thermal melting profile of PfLysRS in the presence of different ligands.
(D) Thermal melting profile of HsLysRS in the presence of different ligands.
(E) Thermal melting profile of Pf-like human LysRS in the presence of different ligands. Each curve in (C–E) is an average of eight measurements.
(F) Diagram of the melting temperatures of PfLysRS, HsLysRS, and Pf-like human LysRS in the presence of different ligands. Error bars represent SDs of eight
repeats.
(G) Thermal melting profile of PfLysRS in combination of CP and different amino acids. Each curve is an average of four measurements.
(H) Diagram of the melting temperatures of PfLysRS in combination of CP and different amino acids. Error bars represent SDs of four repeats (see also Figures S3
and S4).
RFU, relative fluorescence units.about 8,000-fold selectivity for pathogenic over mammalian
IleRS (Hughes and Mellows, 1980). This ultra-high specificity is
mainly attributed to the pyran ring structure of mupirocin, which
interacts with two bacterial/archaeal specific residues (H581 and
L583) located at the C terminus of the last b strand of the Ross-
mann fold and is not conserved in eukaryotic IleRSs (Nakama
et al., 2001). CP inhibits PfLysRS with 1,000-fold higher po-Chemistry & Biology 22,tency than HsLysRS in a yeast-growth-based assay (Hoepfner
et al., 2012). The two enzymes have veryminor differences within
the active center as revealed by our structural studies, involving
only three residues: P300, Q321, and T337 (Figure 3). Further,
mutagenesis of these residues from human to Plasmodium
counterparts failed to increase the interactions with CP (Fig-
ure 3D). Similarly, mutagenesis of the Q324 and T340 in yeast734–744, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 741
Table 2. Response of Ligand/Inhibitor Binding on Thermal Shift
PfLysRS HsLysRS Pf-like Human LysRS
DTm
(C)
Kd
(mM)
DTm
(C)
Kd
(mM)
DTm
(C)
Kd
(mM)
Lysine 2.7 34.1 0.1 84.9 0.2 ND
ATP (no lysine) 0.5 ND 0.2 ND 0.9 ND
ATP (with lysine) 0.6 2.8 0.9 2.8 0.9 2.2
CP (no lysine) 2.4 1.5 0.8 ND 1.1 ND
CP (with lysine) 14.4 0.0024 0.3 3.3 1.0 2.1
ND, not determined because of negative DTm.increased only 4% sensitivity (Hoepfner et al., 2012). Interest-
ingly, our studies demonstrate that CP together with lysine stabi-
lized PfLysRS 7-fold stronger than CP alone (17.1C increase
versus 2.4C), in a manner that is strictly dependent on cognate
amino acid binding with no effect found for other amino acids
(Figure 4). These results suggest that the highly specific inhibition
to Plasmodium cells versus human cells by CPmay be facilitated
by the naturally existing L-lysine in cells.
While CP and lysine can be equally accommodated in
PfLysRS and human enzymes with a similar amount of atomic
contacts (Figure 3D), structural and sequence analysis reveals
that the divergence of PfLysRS beyond the active site center
may lead to the preferential inhibition ofPfLysRSbyCP (Figure 4).
Only PfLysRS, but not human LysRS, could be stabilized by
K-CP for a huge (17.1C) increase in thermal melting test (Fig-
ure 4C). This corresponds to a Kd of 2.4 nM for the interaction
(Table 2). Interestingly, without ligands, PfLysRS has a 7C
lower melting temperature thanHsLysRS (Figure 4F), suggesting
PfLysRS itself may be more flexible and less stable than
HsLysRS. This difference is further evidenced by the finding of
destabilization in residues 518–535 of PfLysRS (Figure S4A,
S4B). PfLysRS contains a specific disulfide bond (C517–C540),
which encloses this region (Figure S4A and S4B) and is located
14.5 A˚ away from lysine and 24.3 A˚ away from the bound CP.
This disulfide bond appears to be PfLysRS-specific and does
not exist in any other solved LysRS structure so far. Particularly,
the first cysteine (C517) is present only in Plasmodium species
but substituted by a conserved leucine residue in higher eukary-
otes and an arginine in lower eukaryote and bacteria (Fig-
ure S4C). In contrast, residues within the disordered region
(518–535) are more conserved across different species. In fact,
the second cysteine (C540) is strictly conserved in eukaryotes,
suggesting C540 is important for the activity of LysRS. It is plau-
sible that the Plasmodium-specific disulfide bound may play a
mechanistic role by protecting the cysteine residues from being
oxidized in their highly oxidative environments such as red blood
cells (Mohanty et al., 2014).
SIGNIFICANCE
Collectively, these studies exhibit the molecular basis for
specific inhibition of a tRNA synthetase by an ATP site
competitive inhibitor, to achieve both the horizontal selec-
tivity among all aaRS families and the longitudinal specificity
across different species. CP specifically stabilized the
PfLysRS in the presence of L-lysine, and the effect is depen-742 Chemistry & Biology 22, 734–744, June 18, 2015 ª2015 Elsevierdent on the overall structural flexibility. This study suggests
that the inherent divergence of tRNA synthetase structural
assembly plus the cooperative binding of amino acid may
allow for highly specific inhibition of aaRS, with potential
instrumental implication in drug development.
EXPERIMENTAL PROCEDURES
Protein Preparation
Untagged HsLysRS (70–584) was constructed in vector pET20b. The N-termi-
nal human P38/AIMP2 sequence (1–36) was cloned into vector pET28a with a
C-terminal 6xHis tag. The two protein/peptides were co-expressed in BL21
(DE3) strain with 0.2 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) for
20 hr at 16C. The cell pellet (from 4 to 8 l) was lysed in low salt buffer
(150 mM NaCl, 20 mM Tris-HCl [pH 8.0], and 15 mM imidazole), loaded onto
a Ni-HiTrap column (GEHealthcare, 5ml) andwashed with low salt buffer. Pro-
tein was eluted with low salt elution buffer (150 mM NaCl, 20 mM Tris-HCl
[pH 8.0], and 250 mM imidazole). To remove free p38, the Ni-HiTrap purified
HsLysRS:p3836-His proteins were concentrated and then purified by gel filtra-
tion Superdex 200 column (GE Healthcare, 10/300 GL) with running buffer
(20 mM HEPES-Na [pH 7.5], and 150 mM NaCl). The peak fractions of
HsLysRS: p3836 complex were then concentrated for crystallization.
Pf-like human LysRS plasmid was made by PCR-based mutagenesis from
the HsLysRS plasmid, with the mutations P300T, Q321V, and T337S. The pro-
tein was also co-expressed and co-purified with p3836 similar to the above.
PfLysRS (77–583)was constructed in vector pET20b,with aC-terminal 6xHis
tag. The protein was expressed in BL21 (DE3) strain with 0.2 mM IPTG for 20 hr
at 16C. The cell pellet (from 4 to 8 l) was lysed in NTA-wash buffer (500 mM
NaCl, 20mMTris-HCl [pH 8.0], 15mM imidazole), loaded onto a Ni-HiTrap col-
umn and washed with NTA-wash buffer. Protein was eluted with NTA-elution
buffer (500 mM NaCl, 20 mM Tris-HCl [pH 8.0], 250 mM imidazole). Then the
proteinwasconcentratedand further purifiedbygel filtrationSuperdex200col-
umn with running buffer (20 mM Hepes-Na [pH 7.5], 150 mM NaCl). The peak
fractions were then concentrated for crystallization.
Crystallization
All crystallizations were done by the sitting drop method. To obtain HsLysRS-
K-CP complex crystals, 30 mg/ml HsLysRS:p3836 was premixed with 5 mM
L-lysine at 4C, and was crystallized by mixing 0.5 ml of protein solution with
0.5 ml of precipitant solution, containing 8% PEG20000, 0.1 M Tris [pH 8.0],
and 0.1 M sodium chloride. After incubation at 18C for 3 to 7 days, crystals
were transferred to a drop containing 8% PEG20000, 0.1 M Tris [pH 8.0],
0.1 M sodium chloride, and 3 mM CP. The 72-hr soaked crystals were flash-
frozen in liquid nitrogen for data collection with the cryo solution containing
8% PEG20000, 0.1 M Tris [pH 8.0], 0.1 M sodium chloride, 3 mM CP, and
25% glycerol.
To obtain Pf-like LysRS-K-CP complex crystals, protein (15mg/ml) was pre-
mixed with 5 mM lysine and 2 mM CP at 4C and was crystallized by mixing
0.5 ml of protein solution with 0.5 ml of precipitant solution, containing 25%
PEG4000, and 0.1 M MES [pH 6.5]. After incubation at 18C for 3 to 7 days,
crystals were flash-frozen in liquid nitrogen for data collection with the cryo
solution containing 20% PEG4000, 0.8 M MES [pH 8.0], and 20% glycerol.
To obtain PfLysRS-CP crystals, PfLysRS protein (15 mg/ml) was premixed
with 2 mM CP at 4C and was crystallized by mixing 0.5 ml of protein solution
with 0.5 ml of precipitant solution, containing 0.2 M trisodium citrate, and 20%
PEG3350. After incubation at 18C for 3 to 7 days, crystals were flash-frozen in
liquid nitrogen for data collection with the cryo solution containing 0.16 M tri-
sodium citrate, 16% PEG3350, and 20% glycerol.
Structure Determination
HsLysRS-K-CP datasets were obtained from beamline LS-CAT 21-ID-F at the
Advanced Photon Source (Argonne, IL). Pf-like LysRS-K-CP and PfLysRS-CP
datasets were obtained from beamline BL7-1 at the Stanford Synchrotron Ra-
diation Lightsource (Menlo Park, CA). All data were integrated and scaled with
HKL2000 (Otwinowski and Minor, 1997). The structures were determined by
molecular replacement based on the human LysRS structure (PDB: 3BJU)
in the Molrep program (CCP4, 1994). After corrections for bulk solvent andLtd All rights reserved
overall B values, data were refined by iterative cycles of positional refinement
and TLS refinement with PHENIX (Adams et al., 2010) and model building with
COOT (Emsley et al., 2010). All current models have good geometry and no
residues are in the disallowed region of the Ramachandran plot. Data collec-
tion and model statistics are given in Table 1.
Calculation of Atomic Contacts
The atomic contacts are calculated by the CCP4 supported program
CONTACT (Winn et al., 2011).
Thermal Shift Assay
Proteins (PfLysRS, HsLysRS, and Pf-like LysRS) were first prepared as a 2x
mixture, by diluting proteins at 4 mM concentration in buffer containing
20mMTris-HCl [pH 8.], 200mMNaCl, 5mMDTT, and different concentrations
of ligand or inhibitors (CP, 40 mM; lysine, 1mM; ATP, 40 mM; CaCl2, 2 mM). The
2xmixture was incubated at room temperature for 30min and chilled on ice for
5 min. Then the 2x Protein Thermal Shift Dye (Life Technologies), which was
pre-diluted in buffer containing 20 mM Tris-HCl [pH 8.0], 200 mM NaCl, and
5 mM DTT, was added to the 2x mixture by 1:1 ratio on ice. After complete
mixing, the final solutions were heated from 10C to 90C at a rate of 1C/
min and fluorescence signals were monitored by iQTM5 Real-Time PCR
Detection System (Bio-Rad).
The method for calculating Kd was described earlier (Pantoliano et al.,
2001). First, a nonlinear least squares fitting algorithm was used to fit the fluo-
rescence curve using the following expression:
yðTÞ=yu+ yf  yu
1+ expf  DHu=R½1=T  1=Tm+DCpu=R½lnðT=TmÞ+Tm=T  1g ;
where y(T) is the fluorescence unfolding data, R is the gas constant, and the
five fitting parameters, Tm, DHu, DCpu, yf, and yu, are allowed to float accord-
ing to the Levenberg-Marquardt algorithm for minimizing the sum of the
squares of the residuals. Tm is the midpoint for the protein unfolding transition.
DHu is the protein unfolding enthalpy. DCpu is the heat capacity change for
protein unfolding. yf and yu are the pretransitional and posttransitional fluores-
cence intensity levels, respectively. Then the dissociation constant at Tm
(KdTm) is calculated using the following expression:
KdTm=
½LTm
expf DHuT0=R½1=Tm 1=T0+DCpuT0=R½lnðTm=T0Þ+T0=Tm  1g ;
where [L]Tm is the free ligand concentration at Tm, which can be estimated by
[L]Total. T0 is the midpoint for the protein unfolding transition in the absence of
ligand. DHuT0 is the enthalpy of protein unfolding in the absence of ligand.
DCpuT0 is the heat capacity change for protein unfolding in the absence of
ligand. Finally the Kd at any temperature KdT (25C/298 K was used in this
study) can be estimated by the expression:
KdT =
KdTm
expf62760=R½1=T  1=Tmg ;
where 62,760 (J/mol) is a reasonable estimation of the ligand binding enthalpy
(Pantoliano et al., 2001).
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